Fate therapeutics reports fourth quarter 2020 financial results and highlights operational progress

Positive interim data reported from ft516 phase 1 study in relapsed / refractory bcl; objective responses, including two complete responses, achieved in 3 of 4 patients in dose cohorts 2 and 3

FATE Ratings Summary

FATE Quant Ranking